5 completed. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 2 | 1 | Completed 1 |
Follow Pure Autonomic Failure: new trials by email Literature Review of Pure Autonomic Failure trials Research Report on Pure Autonomic Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Completed | Theravance Biopharma | 195 | 2019-01-24 | 2022-09-14 |
| Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Double blinded IVIg, Double blinded Placebo, Single Blinded IVIg - Autoimmune Autonomic Ganglionopathy (AAG) | Phase 2 / Phase 3 | Completed | Beth Israel Deaconess Medical Center | 6 | 2012-02-01 | 2017-07-02 |
| A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Placebo, Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 263 | 2008-09-01 | 2014-05-16 |
| Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Droxidopa, Placebo - Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 103 | 2008-01-01 | 2014-05-16 |
| Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Placebo, Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 181 | 2008-01-01 | 2014-05-20 |
Hypotension, Orthostatic (4) · Multiple System Atrophy (4) · dopamine beta hydroxylase deficiency (3) · Autonomic Nervous System Diseases (1) · Dizziness (1) · Hypotension (1) · Parkinson Disease (1) · Parkinsonian Disorders (1) · Syncope (1)
Cardiovascular Diseases (5) · Nervous System Diseases (5) · Primary Dysautonomias (5) · Vascular Diseases (5) · Autonomic Nervous System Diseases (4) · Basal Ganglia Diseases (4) · Brain Diseases (4) · Central Nervous System Diseases (4) · Hypotension (4) · Movement Disorders (4) · Neurodegenerative Diseases (4) · Orthostatic Intolerance (4) · Synucleinopathies (4) · Consciousness Disorders (1) · Neurobehavioral Manifestations (1)
Droxidopa (3) · Immunoglobulins, Intravenous (1) · ampreloxetine (1)
Chelsea Therapeutics (3) · Beth Israel Deaconess Medical Center (1) · Theravance Biopharma (1)
United States (5) · Canada (4) · Australia (3) · New Zealand (3) · Austria (1) · Bulgaria (1) · Denmark (1) · Estonia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · Portugal (1)
Roy Freeman, MD (2) · Alberto Vasquez, MD (1) · Alvin McElveen, MD (1) · Brent Goodman, MD (1) · Christopher J Mathias, MD (1) · Christopher J. Mathias, MD (1) · Horacio Kaufmann Kaufmann, MD (1) · Horacio Kaufmann, MD (1) · Mazen Dimachkie, MD (1) · Phillip A Low, MD (1) · Richard Hull, MD (1) · Stephen Greer, MD (1)
PMID 27538531, PMID 28494751, PMID 25350981, PMID 42475649
2018 (1), U54NS065736 (1)